커넥티드 의료기기 시장 : 제품 유형, 접속 기술, 최종 사용자, 용도, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Connected Medical Devices Market is projected to grow by USD 291.37 billion at a CAGR of 23.29% by 2032.

Connected Medical Devices Executive Summary

Connected medical devices are becoming core infrastructure for modern care delivery, linking diagnostic equipment, wearables, implantables, remote patient monitoring systems, infusion pumps, imaging platforms, and hospital networks through secure data exchange. Demand is supported by verified structural drivers: the World Health Organization reports that noncommunicable diseases account for 41 million deaths annually, and the United Nations projects that one in six people globally will be aged 60 or older by 2030.

The market is shifting from isolated hardware toward interoperable, software-enabled ecosystems that improve clinical visibility, continuity of care, and operational efficiency. Regulatory expectations are rising in parallel, with U.S. FDA cybersecurity requirements under FDORA, EU MDR obligations, GDPR privacy rules, and IMDRF software guidance shaping product design, post-market monitoring, and evidence generation.

Transformative Shifts in Connected Device Adoption

The connected medical devices landscape is being transformed by remote patient monitoring, hospital-at-home programs, digital therapeutics, cloud-based device management, and standards-based interoperability. In the United States, CMS reimbursement pathways for remote physiologic monitoring and remote therapeutic monitoring have accelerated provider adoption, while ONC rules under the 21st Century Cures Act have strengthened demand for API-enabled health data exchange.

Cybersecurity, usability, and lifecycle software governance are now competitive differentiators. FDA premarket cybersecurity expectations, EU MDR clinical evaluation requirements, and global focus on software as a medical device are pushing manufacturers to design connected products with secure-by-design architecture, real-world performance monitoring, and upgradeable platforms.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of connected medical devices by converting continuous device data into clinical decision support, predictive maintenance, patient risk stratification, workflow automation, and personalized therapy optimization. The FDA public list of AI and machine learning-enabled medical devices has grown to more than 950 authorized devices, demonstrating rapid clinical validation across radiology, cardiology, neurology, and patient monitoring.

AI also increases governance requirements. Connected medical device companies must maintain transparent model performance, cybersecurity controls, bias monitoring, data provenance, and post-market surveillance. The EU AI Act, FDA guidance on AI-enabled device lifecycle management, and emerging good machine learning practice principles are making AI assurance central to market access and trust.

Key Regional Insights for Connected Medical Devices

Asia-Pacific is one of the fastest-moving regions for connected medical devices, supported by aging populations in Japan, South Korea, and China, large-scale digital health programs in India, and strong electronics manufacturing capacity across China, Japan, South Korea, Singapore, and Taiwan. North America remains a leading innovation and commercialization hub due to FDA pathways, mature hospital IT infrastructure, remote patient monitoring reimbursement, venture funding, and broad adoption of cloud and analytics in care delivery.

Europe is shaped by EU MDR, GDPR, the EU AI Act, and the European Health Data Space, which together place strong emphasis on safety, privacy, interoperability, artificial intelligence governance, and cross-border health data use. Latin America is expanding through telehealth, private hospital modernization, and chronic disease management needs in Brazil and Mexico. The Middle East is investing in digital hospitals and smart health systems, particularly in GCC markets, while Africa shows long-term potential as mobile health, donor-backed digital infrastructure, and remote diagnostics address access gaps across dispersed populations.

Key Group Insights Across Strategic Economic Blocs

ASEAN demand is being driven by hospital modernization, medical tourism, and expanding digital health strategies in Singapore, Malaysia, Thailand, Indonesia, and Vietnam. GCC countries are prioritizing connected care through national health transformation programs, smart hospitals, and cloud-enabled healthcare infrastructure. The European Union is advancing a regulated innovation model through MDR, GDPR, AI Act implementation, and the European Health Data Space, making compliance, interoperability, and data protection central to connected medical device adoption.

BRICS markets combine scale, manufacturing depth, and public health demand, with China and India shaping high-volume device deployment while Brazil and South Africa expand connected care in urban health systems. G7 countries remain central to premium device innovation, reimbursement development, clinical evidence standards, and cybersecurity policy. NATO members are increasingly relevant to supply chain resilience, secure medical infrastructure, and cybersecurity alignment for connected healthcare environments, particularly as medical device networks become part of critical health infrastructure.

Key Country Insights for Priority Markets

The United States leads in connected medical device innovation, FDA authorization activity, remote patient monitoring reimbursement, and hospital technology spending, while Canada emphasizes publicly funded digital health, privacy compliance, and remote care for geographically distributed populations. Mexico benefits from medical device manufacturing strength and cross-border supply chains, while Brazil is Latin America's largest healthcare market and is expanding telehealth and chronic care infrastructure.

In Europe, the United Kingdom supports digital health through NHS transformation and MHRA regulatory reform; Germany benefits from strong medtech manufacturing and DiGA digital health pathways; France is investing in digital health sovereignty; Italy and Spain are modernizing hospital systems; and Russia remains shaped by localization requirements and sanctions-related procurement constraints. In Asia-Pacific, China combines scale, policy support, and domestic manufacturing; India is expanding through Ayushman Bharat Digital Mission and large chronic disease demand; Japan has strong aging-care needs and PMDA oversight; Australia emphasizes national digital health records and rural access; and South Korea is advanced in electronics, 5G, and hospital digitization.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize secure-by-design engineering, interoperability based on recognized standards such as HL7 FHIR, scalable cloud connectivity, and lifecycle cybersecurity management from concept through post-market support. Product roadmaps should align early with FDA, EU MDR, GDPR, EU AI Act, and local data protection expectations to reduce approval delays and commercial risk.

Companies should build evidence strategies around clinical outcomes, workflow efficiency, health economics, cybersecurity resilience, and real-world performance. Strategic partnerships with hospitals, cloud infrastructure providers, cybersecurity specialists, payers, standards bodies, and regional distributors can accelerate adoption while improving localization, service reliability, and trust.

Research Methodology

This executive summary is developed through secondary research using publicly available and verifiable sources, including regulatory guidance, public health data, government digital health strategies, reimbursement frameworks, standards organizations, and cybersecurity directives. Key reference points include FDA device and cybersecurity guidance, EU MDR and GDPR frameworks, the EU AI Act, WHO disease burden data, UN demographic projections, IMDRF software principles, and national digital health programs.

The analysis evaluates demand drivers, regulatory conditions, regional adoption patterns, technology maturity, competitive dynamics, cybersecurity requirements, interoperability policies, and macroeconomic influences. Findings are synthesized to support strategic planning, market prioritization, and executive-level decision-making in connected medical devices.

Conclusion

Connected medical devices are moving from optional digital enhancements to essential infrastructure for preventive care, chronic disease management, hospital efficiency, and patient-centered healthcare delivery. Adoption is being reinforced by aging demographics, rising chronic disease prevalence, interoperability mandates, remote care reimbursement, cybersecurity requirements, and cloud-enabled clinical operations.

The next phase of leadership will depend on trusted connectivity, regulatory readiness, cyber resilience, AI governance, and proven clinical value. Organizations that combine secure device engineering with measurable outcomes and regional market adaptation will be best positioned to strengthen competitive positioning and support sustainable adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Connected Medical Devices Market, by Product Type

• 7.1. Diagnostic Devices
  • 7.1.1. Imaging Systems
  • 7.1.2. Point Of Care Test Kits
  • 7.1.3. Ultrasound Devices
• 7.2. Monitoring Devices
  • 7.2.1. ECG Monitor
  • 7.2.2. Glucose Monitor
  • 7.2.3. Vital Signs Monitor
• 7.3. Surgical Devices
  • 7.3.1. Electrosurgical Devices
  • 7.3.2. Endoscopic Devices
  • 7.3.3. Robotic Surgery Systems
• 7.4. Therapeutic Devices
  • 7.4.1. Dialysis Systems
  • 7.4.2. Infusion Pumps
  • 7.4.3. Ventilators
• 7.5. Wearable Devices
  • 7.5.1. Fitness Trackers
  • 7.5.2. Smart Watches

8. Connected Medical Devices Market, by Connectivity Technology

• 8.1. Bluetooth
• 8.2. Cellular
• 8.3. NFC
• 8.4. Wi Fi
• 8.5. Zigbee

9. Connected Medical Devices Market, by End User

• 9.1. Ambulatory Care Centers
• 9.2. Clinics
• 9.3. Diagnostic Centers
• 9.4. Home Care Settings
  • 9.4.1. Elderly Care
  • 9.4.2. Post Operative Care
• 9.5. Hospitals
  • 9.5.1. Private Hospitals
  • 9.5.2. Public Hospitals

10. Connected Medical Devices Market, by Application

• 10.1. Drug Delivery
  • 10.1.1. Infusion Drug Delivery
  • 10.1.2. Inhalation Systems
  • 10.1.3. Injection Drug Delivery
• 10.2. Imaging
  • 10.2.1. CT
  • 10.2.2. MRI
  • 10.2.3. Ultrasound Imaging
  • 10.2.4. X Ray
• 10.3. Patient Monitoring
  • 10.3.1. Ambulatory Monitoring
  • 10.3.2. Critical Care Monitoring
  • 10.3.3. Remote Monitoring
• 10.4. Rehabilitation
  • 10.4.1. Neurorehabilitation
  • 10.4.2. Occupational Therapy
  • 10.4.3. Physical Therapy
• 10.5. Surgical Assistance
  • 10.5.1. Navigation Systems
  • 10.5.2. Robotic Assistance
• 10.6. Telehealth
  • 10.6.1. Remote Diagnosis
  • 10.6.2. Remote Patient Monitoring
  • 10.6.3. Video Consultation

11. Connected Medical Devices Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Connected Medical Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Connected Medical Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Connected Medical Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Aerotel Medical System Ltd.
• 16.3. AgaMatrix, Inc. by i-SENS, Inc.
• 16.4. Ambrosia Systems, Inc.
• 16.5. Apple Inc.
• 16.6. Baxter International Inc.
• 16.7. Becton Dickinson and Company
• 16.8. Boston Scientific Corporation
• 16.9. Dexcom Inc.
• 16.10. Draeger Medical Systems, Inc.
• 16.11. F. Hoffmann-La Roche Ltd
• 16.12. Fitbit by Google LLC
• 16.13. Fresenius Medical Care AG & Co. KGaA
• 16.14. Garmin Ltd.
• 16.15. GE Healthcare Inc.
• 16.16. Honeywell International Inc.
• 16.17. ICU Medical, Inc.
• 16.18. iHealth Labs Inc.
• 16.19. Insulet Corporation
• 16.20. Johnson & Johnson Services Inc.
• 16.21. Koninklijke Philips N.V.
• 16.22. L&T Technology Services Limited
• 16.23. Masimo Corporation
• 16.24. Medtronic plc
• 16.25. Microlife Corporation
• 16.26. Molex, LLC. by Koch Industries, Inc.
• 16.27. Omron Corporation
• 16.28. Qualcomm Technologies, Inc.
• 16.29. ResMed Inc.
• 16.30. Samsung Electronics Co. Ltd.
• 16.31. Siemens Healthineers AG
• 16.32. Silicon & Software Systems Ltd.
• 16.33. Silicon Laboratories
• 16.34. Smart Meter, LLC
• 16.35. Stream Product Development, Inc.
• 16.36. Stryker Corporation
• 16.37. Zimmer Biomet Holdings Inc.